TriangleNCT00005044 · OUTCOME
Disease-free Survival (DFS) (10-year Rates Reported)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
What was measured
Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.
Analysis population: Eligible patients without follow-up data
Groups in this outcome
TAS x 8 Weeks
Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
TAS x 28 Weeks
TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
| Group | Source count |
|---|---|
| TAS x 8 Weeks | 752 |
| TAS x 28 Weeks | 737 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| TAS x 8 Weeks | 24 | Not reported | 20 | 27 | Not reported |
| TAS x 28 Weeks | 23 | Not reported | 20 | 27 | Not reported |
Source statistical analyses
- ci Lower Limit
- 0.85
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.08
- estimate Comment
- Reference level = TAS x 8 weeks
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.47
- param Type
- Hazard Ratio (HR)
- param Value
- 0.96
- statistical Comment
- Significance level = 0.05
- statistical Method
- Log Rank
Complete source fields
- analyses
- ci Lower Limit
- 0.85
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.08
- estimate Comment
- Reference level = TAS x 8 weeks
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.47
- param Type
- Hazard Ratio (HR)
- param Value
- 0.96
- statistical Comment
- Significance level = 0.05
- statistical Method
- Log Rank
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 20
- upper Limit
- 27
- value
- 24
- group Id
- OG001
- lower Limit
- 20
- upper Limit
- 27
- value
- 23
- denoms
- counts
- group Id
- OG000
- value
- 752
- group Id
- OG001
- value
- 737
- units
- Participants
- description
- Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
- id
- OG000
- title
- TAS x 8 Weeks
- description
- TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
- id
- OG001
- title
- TAS x 28 Weeks
- param Type
- NUMBER
- population Description
- Eligible patients without follow-up data
- reporting Status
- POSTED
- time Frame
- From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
- title
- Disease-free Survival (DFS) (10-year Rates Reported)
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice